Zhuhai Rundu Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002923.SZ

Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2023: USD 31.10 M

Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA is USD 31.10 M for the year ending December 31, 2023, a -19.45% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 38.61 M, a 8.06% change year over year.
Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 35.73 M, a 16.27% change year over year.
Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 30.73 M, a 17.55% change year over year.
Zhuhai Rundu Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 26.14 M, a 18.42% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 002923.SZ

Zhuhai Rundu Pharmaceutical Co., Ltd.

CEO	Mr. Jie Liu
IPO Date	Jan. 5, 2018
Location	China
Headquarters	No. 6, North Airport Road
Employees	1,945
Sector	Health Care
Industries Pharmaceuticals

Description

Zhuhai Rundu Pharmaceutical Co., Ltd., a pharmaceutical company, develops, produces, and markets pharmaceutical ingredients for cardiovascular, gastrointestinal, CNS, and anesthesia areas in China and internationally. It offers APIs, intermediates, FDF, and pellets, as well as formulations in the forms of capsules, tablets, and injections. The company was founded in 1997 and is headquartered in Zhuhai, China.

Key trends

Past 5 years